Zoetis Inc. (NYSE:ZTS) Shares Acquired by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 750.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 281,715 shares of the company's stock after purchasing an additional 248,595 shares during the period. BI Asset Management Fondsmaeglerselskab A S owned about 0.06% of Zoetis worth $45,900,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in ZTS. Callahan Advisors LLC grew its position in shares of Zoetis by 90.4% during the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company's stock valued at $2,135,000 after acquiring an additional 6,221 shares during the period. CIBC Asset Management Inc grew its holdings in Zoetis by 24.1% in the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company's stock valued at $38,617,000 after purchasing an additional 46,050 shares during the period. Pensionfund Sabic increased its position in shares of Zoetis by 55.6% in the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company's stock valued at $1,825,000 after buying an additional 4,000 shares in the last quarter. Schroder Investment Management Group raised its stake in shares of Zoetis by 2.6% during the 4th quarter. Schroder Investment Management Group now owns 245,726 shares of the company's stock worth $40,036,000 after buying an additional 6,169 shares during the period. Finally, PFW Advisors LLC purchased a new position in shares of Zoetis during the 4th quarter valued at approximately $1,764,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Up 0.8 %

Shares of ZTS traded up $1.20 during mid-day trading on Thursday, reaching $152.11. The stock had a trading volume of 1,157,937 shares, compared to its average volume of 2,517,082. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The business's fifty day moving average is $159.06 and its 200 day moving average is $169.10. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33. The firm has a market cap of $67.87 billion, a price-to-earnings ratio of 27.81, a P/E/G ratio of 2.78 and a beta of 0.92.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.31%. The ex-dividend date is Monday, April 21st. Zoetis's payout ratio is 36.56%.

Analysts Set New Price Targets

Several equities research analysts recently commented on ZTS shares. Piper Sandler boosted their price target on shares of Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a report on Thursday, February 27th. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Stifel Nicolaus decreased their price target on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Morgan Stanley cut their price objective on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Finally, Barclays raised their target price on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research report on Friday, February 14th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $214.40.

Insider Buying and Selling

In related news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the sale, the executive vice president now directly owns 15,781 shares in the company, valued at approximately $2,682,770. The trade was a 2.02 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,862 shares of company stock valued at $312,254. 0.16% of the stock is currently owned by insiders.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.